MicroRNAs and polycystic kidney disease

Polycystic kidney disease (PKD), the most common genetic cause of chronic renal failure, is characterized by the presence of numerous fluid-filled cysts in renal parenchyma. Despite recent progress, no FDA-approved therapy is available to retard cyst growth. Here, we review current evidence implicat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drug discovery today. Disease models 2013, Vol.10 (3), p.e137-e143
Hauptverfasser: Noureddine, Lama, Hajarnis, Sachin, Patel, Vishal
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e143
container_issue 3
container_start_page e137
container_title Drug discovery today. Disease models
container_volume 10
creator Noureddine, Lama
Hajarnis, Sachin
Patel, Vishal
description Polycystic kidney disease (PKD), the most common genetic cause of chronic renal failure, is characterized by the presence of numerous fluid-filled cysts in renal parenchyma. Despite recent progress, no FDA-approved therapy is available to retard cyst growth. Here, we review current evidence implicating two groups of microRNAs (miRNAs) – the miR-17∼92 cluster and miR-200s – in the pathogenesis of PKD. We present a new hypothesis for cyst growth involving miRNAs and regulation of PKD gene dosage. We propose that manipulating miRNA function in an attempt to normalize PKD gene dosage represents a novel therapeutic strategy in PKD.
doi_str_mv 10.1016/j.ddmod.2013.10.001
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4159181</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1740675713000145</els_id><sourcerecordid>1826601583</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4441-8f27956bf951243d80f387084f967e85a1df31c7258e8070424bdedb076528fc3</originalsourceid><addsrcrecordid>eNp9kE1Lw0AQhhdRbK3-AkF600vjzn5kNweFUvyCqiB6XpLdiW5Nk5pNC_33praWevE0w8w77zs8hJwCjYBCfDmJnJtWLmIUeDuJKIU90gUl6CBWUu3v9B1yFMKEUi4Srg5Jh0nGIKaqS84fva2rl6dh6Kel68-qYmmXofG2_-ldicu-8wHTgMfkIE-LgCeb2iNvtzevo_vB-PnuYTQcD6wQAgY6ZyqRcZYnEpjgTtOca0W1yJNYoZYpuJyDVUxq1FRRwUTm0GVUxZLp3PIeuV77zubZFJ3FsqnTwsxqP03rpalSb_5uSv9h3quFESAT0NAaXGwM6uprjqExUx8sFkVaYjUPBjSLYwpS81bK19KWQAg15tsYoGaF2EzMD2KzQrwatojbq7PdD7c3v0xbwdVagC2nhcfaBOuxtOh8jbYxrvL_BnwDGcSMdQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1826601583</pqid></control><display><type>article</type><title>MicroRNAs and polycystic kidney disease</title><source>Elsevier ScienceDirect Journals</source><creator>Noureddine, Lama ; Hajarnis, Sachin ; Patel, Vishal</creator><creatorcontrib>Noureddine, Lama ; Hajarnis, Sachin ; Patel, Vishal</creatorcontrib><description>Polycystic kidney disease (PKD), the most common genetic cause of chronic renal failure, is characterized by the presence of numerous fluid-filled cysts in renal parenchyma. Despite recent progress, no FDA-approved therapy is available to retard cyst growth. Here, we review current evidence implicating two groups of microRNAs (miRNAs) – the miR-17∼92 cluster and miR-200s – in the pathogenesis of PKD. We present a new hypothesis for cyst growth involving miRNAs and regulation of PKD gene dosage. We propose that manipulating miRNA function in an attempt to normalize PKD gene dosage represents a novel therapeutic strategy in PKD.</description><identifier>ISSN: 1740-6757</identifier><identifier>EISSN: 1740-6757</identifier><identifier>DOI: 10.1016/j.ddmod.2013.10.001</identifier><identifier>PMID: 25221607</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><ispartof>Drug discovery today. Disease models, 2013, Vol.10 (3), p.e137-e143</ispartof><rights>2013 Elsevier Ltd</rights><rights>2013 Elsevier Ltd. All rights reserved. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4441-8f27956bf951243d80f387084f967e85a1df31c7258e8070424bdedb076528fc3</citedby><cites>FETCH-LOGICAL-c4441-8f27956bf951243d80f387084f967e85a1df31c7258e8070424bdedb076528fc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1740675713000145$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3536,4009,27902,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25221607$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Noureddine, Lama</creatorcontrib><creatorcontrib>Hajarnis, Sachin</creatorcontrib><creatorcontrib>Patel, Vishal</creatorcontrib><title>MicroRNAs and polycystic kidney disease</title><title>Drug discovery today. Disease models</title><addtitle>Drug Discov Today Dis Models</addtitle><description>Polycystic kidney disease (PKD), the most common genetic cause of chronic renal failure, is characterized by the presence of numerous fluid-filled cysts in renal parenchyma. Despite recent progress, no FDA-approved therapy is available to retard cyst growth. Here, we review current evidence implicating two groups of microRNAs (miRNAs) – the miR-17∼92 cluster and miR-200s – in the pathogenesis of PKD. We present a new hypothesis for cyst growth involving miRNAs and regulation of PKD gene dosage. We propose that manipulating miRNA function in an attempt to normalize PKD gene dosage represents a novel therapeutic strategy in PKD.</description><issn>1740-6757</issn><issn>1740-6757</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNp9kE1Lw0AQhhdRbK3-AkF600vjzn5kNweFUvyCqiB6XpLdiW5Nk5pNC_33praWevE0w8w77zs8hJwCjYBCfDmJnJtWLmIUeDuJKIU90gUl6CBWUu3v9B1yFMKEUi4Srg5Jh0nGIKaqS84fva2rl6dh6Kel68-qYmmXofG2_-ldicu-8wHTgMfkIE-LgCeb2iNvtzevo_vB-PnuYTQcD6wQAgY6ZyqRcZYnEpjgTtOca0W1yJNYoZYpuJyDVUxq1FRRwUTm0GVUxZLp3PIeuV77zubZFJ3FsqnTwsxqP03rpalSb_5uSv9h3quFESAT0NAaXGwM6uprjqExUx8sFkVaYjUPBjSLYwpS81bK19KWQAg15tsYoGaF2EzMD2KzQrwatojbq7PdD7c3v0xbwdVagC2nhcfaBOuxtOh8jbYxrvL_BnwDGcSMdQ</recordid><startdate>2013</startdate><enddate>2013</enddate><creator>Noureddine, Lama</creator><creator>Hajarnis, Sachin</creator><creator>Patel, Vishal</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2013</creationdate><title>MicroRNAs and polycystic kidney disease</title><author>Noureddine, Lama ; Hajarnis, Sachin ; Patel, Vishal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4441-8f27956bf951243d80f387084f967e85a1df31c7258e8070424bdedb076528fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Noureddine, Lama</creatorcontrib><creatorcontrib>Hajarnis, Sachin</creatorcontrib><creatorcontrib>Patel, Vishal</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Drug discovery today. Disease models</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Noureddine, Lama</au><au>Hajarnis, Sachin</au><au>Patel, Vishal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MicroRNAs and polycystic kidney disease</atitle><jtitle>Drug discovery today. Disease models</jtitle><addtitle>Drug Discov Today Dis Models</addtitle><date>2013</date><risdate>2013</risdate><volume>10</volume><issue>3</issue><spage>e137</spage><epage>e143</epage><pages>e137-e143</pages><issn>1740-6757</issn><eissn>1740-6757</eissn><abstract>Polycystic kidney disease (PKD), the most common genetic cause of chronic renal failure, is characterized by the presence of numerous fluid-filled cysts in renal parenchyma. Despite recent progress, no FDA-approved therapy is available to retard cyst growth. Here, we review current evidence implicating two groups of microRNAs (miRNAs) – the miR-17∼92 cluster and miR-200s – in the pathogenesis of PKD. We present a new hypothesis for cyst growth involving miRNAs and regulation of PKD gene dosage. We propose that manipulating miRNA function in an attempt to normalize PKD gene dosage represents a novel therapeutic strategy in PKD.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>25221607</pmid><doi>10.1016/j.ddmod.2013.10.001</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1740-6757
ispartof Drug discovery today. Disease models, 2013, Vol.10 (3), p.e137-e143
issn 1740-6757
1740-6757
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4159181
source Elsevier ScienceDirect Journals
title MicroRNAs and polycystic kidney disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T23%3A35%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MicroRNAs%20and%20polycystic%20kidney%20disease&rft.jtitle=Drug%20discovery%20today.%20Disease%20models&rft.au=Noureddine,%20Lama&rft.date=2013&rft.volume=10&rft.issue=3&rft.spage=e137&rft.epage=e143&rft.pages=e137-e143&rft.issn=1740-6757&rft.eissn=1740-6757&rft_id=info:doi/10.1016/j.ddmod.2013.10.001&rft_dat=%3Cproquest_pubme%3E1826601583%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1826601583&rft_id=info:pmid/25221607&rft_els_id=S1740675713000145&rfr_iscdi=true